As Met and Mcl‐1 are components of the STAT3 signalling pathway, they are also related to the acquired resistance to AZD9291.31, 32 Our data showed that DYRK1A suppression could reverse the activation of Met and Mcl‐1 that was induced by AZD9291 in NSCLC cells, indicating that targeting DYRK1A might be effective for overcoming AZD9291 resistance, but further experiments are required to confirm this hypothesis. The gene discussed is MCL1; the disease is non-small cell lung carcinoma.